CYCLOPHOSPHAMIDE injection, powder, for solution

Страна: США

мова: англійська

Джерело: NLM (National Library of Medicine)

Активний інгредієнт:

CYCLOPHOSPHAMIDE (UNII: 8N3DW7272P) (CYCLOPHOSPHAMIDE ANHYDROUS - UNII:6UXW23996M)

Доступна з:

Baxter Healthcare Corporation

ІПН (Міжнародна Ім'я):

CYCLOPHOSPHAMIDE

Склад:

CYCLOPHOSPHAMIDE ANHYDROUS 500 mg in 25 mL

Адміністрація маршрут:

INTRAVENOUS

Тип рецепту:

PRESCRIPTION DRUG

Терапевтичні свідчення:

Cyclophosphamide is indicated for the treatment of: Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. Pregnancy Category D Risk Summary Cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monke

Огляд продуктів:

Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in vials for single dose use. Cyclophosphamide for Injection, USP Store vials at or below 25°C (77°F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. [see Dosage and Administration (2.3)] . Cyclophosphamide is an antineoplastic product. Follow special handling and disposal procedures.1

Статус Авторизація:

Abbreviated New Drug Application

Характеристики продукта

CYCLOPHOSPHAMIDE- CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION
BAXTER HEALTHCARE CORPORATION
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CYCLOPHOSPHAMIDE SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CYCLOPHOSPHAMIDE.
CYCLOPHOSPHAMIDE FOR INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 1959
INDICATIONS AND USAGE
Cyclophosphamide is an alkylating drug indicated for treatment of:
•
•
DOSAGE AND ADMINISTRATION
MALIGNANT DISEASES: ADULT AND PEDIATRIC PATIENTS(2.1)
•
•
MINIMAL CHANGE NEPHROTIC SYNDROME IN PEDIATRIC PATIENTS (2.2)
•
DOSAGE FORMS AND STRENGTHS
•
CONTRAINDICATIONS
•
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
•
•
MALIGNANT DISEASES: malignant lymphomas: Hodgkin’s disease,
lymphocytic lymphoma, mixed-cell type lymphoma,
histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma,
leukemias, mycosis fungoides, neuroblastoma,
adenocarcinoma of ovary, retinoblastoma, breast carcinoma (1.1)
MINIMAL CHANGE NEPHROTIC SYNDROME IN PEDIATRIC PATIENTS:
biopsy proven minimal change nephrotic syndrome patients who failed to
adequately respond to or are unable to
tolerate adrenocorticosteroid therapy (1.2)
Limitations of Use:
The safety and effectiveness for the treatment of nephrotic syndrome
in adults of other renal disease has not been
e stablishe d.
Intravenous: Initial course for patients with no hematologic
deficiency: 40 mg per kg to 50 mg per kg in divided doses
over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg
given every 7 to 10 days or 3 mg per kg to 5
mg per kg twice weekly.
Oral: Usually 1 mg per kg per day to 5 mg per kg per day for both
initial and maintenance dosing.
Recommended oral dose: 2 mg per kg daily for 8 to 12 weeks (maximum
cumulative dose 168 mg per kg). Treatment
beyond 90 days increases the probability of sterility in males.
Injection, sterile white powder: 500 mg, 1 g, and 2 g (3)
Hypersensitivity to cyclophosphamide (4)
Urinary outflow obstruction